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Abstract The human calcium-independent phospholipase A2
(iPLA2 ; 88 kDa) has recently been cloned (Larsson, P.K.A.,
Claesson, H.-E. and Kennedy, B.P. (1998) J. Biol. Chem. 272,
207^214). Here we demonstrate the expression of the human
iPLA2 mRNA and its splice variants in blood progenitor cells,
immature leukemic cells and mature granulocytes. Chromato-
graphical resolvable iPLA2 activity was found in the cytosolic
fraction of granulocytes and the activity was inhibited by the
iPLA2 inhibitor bromoenol lactone. This drug also inhibited
leukotriene synthesis in human granulocytes, induced by low
concentration of calcium ionophore A23187 (0.10^0.15 WM) or
opsonized zymosan. These results suggest that iPLA2 is involved
in the regulation of the pool of arachidonic acid destined for
leukotriene synthesis in human granulocytes.
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1. Introduction
Phospholipase A2 (PLA2) is a family of enzymes hydrolyz-
ing the acyl ester bond at the sn-2 position in phospholipids
[1,2]. PLA2 enzymes can be subdivided into extracellular or
intracellular forms, based on the enzymes’ localization during
catalysis [2]. Intracellular PLA2s can be further separated into
two groups, calcium-dependent and calcium-independent en-
zymes. Calcium-dependent intracellular enzymes are repre-
sented by the well-studied 85-kDa cytosolic (c) PLA2 [3]. Cal-
cium-independent (i) PLA2s, on the other hand, are a diverse
group of enzymes that have a wide tissue distribution [2,4].
Di¡erent intracellular iPLA2 has been puri¢ed from human
myocardium [5], bovine brain [6], P388D1 murine macro-
phages [7] and rabbit kidney [8]. Recently, much attention
has been focused on an iPLA2 originally puri¢ed from
P388D1 cells [7]. Since this iPLA2 only makes up a minor
fraction of the total cellular protein content and the puri¢ed
enzyme is very unstable, it has been di⁄cult to isolate and
study this enzyme. However, the large scale puri¢cation of
iPLA2 from Chinese hamster ovary (CHO) cells as well as
cDNA cloning and functional expression of the enzyme
have increased our knowledge about the iPLA2 protein [9].
The enzyme does not demonstrate any signi¢cant preference
for fatty acids at the sn-2 position in phospholipids [9]. The
iPLA2 protein contains ankyrin repeats and a GXSXG con-
sensus lipase motif. Ankyrin repeats are suggested to partic-
ipate in protein-protein interactions and may be responsible
for the iPLA2 tetramer formation which is suggested to be the
in vivo active form of the enzyme [9]. Recently, the full length
cDNA sequence for the human form was reported as well as
the expression of multiple splice variants [10]. Interestingly,
two of these iPLA2 splice variants would result in a protein
containing just the N-terminal ankyrin repeats and not the
active site. We have suggested that these forms of the iPLA2
protein could function as in vivo inhibitors of the iPLA2 ac-
tivity because they could render the formation of a tetramer
with one or several monomers that lacked the active site [10].
The murine 85-kDa iPLA2 enzyme is postulated to primar-
ily play a role in membrane phospholipid remodeling and not
in the liberation of arachidonic acid [11,12]. However, the
release of arachidonic acid from smooth muscle cells has
been ascribed to the action of iPLA2 [13]. In fact, the release
of arachidonic acid from smooth muscle cells was triggered by
depletion of intracellular calcium stores rather than an in£ux
of extracellular calcium [13]. Furthermore, arachidonic acid
release has been demonstrated even in the absence of in-
creased cytosolic calcium concentrations in murine macro-
phages [14]. Recently a calcium-independent release of arach-
idonic acid in rat neutrophils through the activation of iPLA2
was described [15] and this release of arachidonic acid was
inhibited by the iPLA2 inhibitor bromoenol lactone (BEL).
Arachidonic acid is the main precursor for important bio-
logical lipid mediators such as leukotrienes (LT) and prosta-
glandins [16]. The liberation of arachidonic acid, destined for
leukotriene synthesis, has traditionally been ascribed to the
activation of one or more calcium-dependent PLA2s. Further-
more, cPLA2 de¢cient mice do not produce leukotrienes or
prostaglandins upon activation with calcium ionophore
A23187 [17]. However, these inbred mice strains also contain
a natural disruption in the sPLA2 (type II) gene which makes
it di⁄cult to draw a more general conclusion about the rela-
tive role of cPLA2 in eicosanoid synthesis in mice [17,18].
Results of anti-sense experiments in human monocytes indi-
cate that there might also be species di¡erences since the syn-
thesis of prostaglandins, but not leukotrienes, was attenuated
in cells treated with anti-sense oligonucleotides against cPLA2
[19]. These studies indicate that di¡erent PLA2 enzymes ap-
pear to be involved in the release of arachidonic acid from
di¡erent membrane phospholipid pools. Thus, the released
arachidonic acid can serve di¡erent functions, such as a pre-
cursor for eicosanoids or as an activator of NADPH oxidase
[15,20]. A recent report demonstrated an increased activity of
calcium-independent PLA2 in HL-60 cells during di¡erentia-
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tion to granulocytes [21]. The aim of the present study was to
investigate the expression of iPLA2 (88 kDa) in myeloid cells
of di¡ering maturity and the role of the enzyme in leukotriene
synthesis in human granulocytes.
2. Materials and methods
2.1. Materials
HPLC solvents were purchased from Rathburn Chemicals (Walker-
burn, UK). Arachidonic acid and (E)-6-(bromomethylene)-3-(1-naph-
thalenyl)-2H-tetrahydropyran-2-one (bromoenol lactone (BEL)) were
from Biomol (Plymouth Meeting, PA, USA). Mono£ow 2 scintillation
liquid was obtained from National Diagnostics (Manville, NJ, USA).
1-Palmitoyl 2-[1-14C]palmitoyl PC (55.5 mCi/mmol) was obtained
from New England Nuclear. FPLC System and the protein puri¢ca-
tion column were from Pharmacia Biotech (Uppsala, Sweden).
2.2. Isolation of cells
Human granulocytes were isolated from concentrates of leukocytes,
obtained from healthy donors at the Karolinska Hospital, by dextran
sedimentation, Lymphoprep (Nycomed) centrifugation and hypotonic
lysis. Cells were thereafter washed twice in phosphate bu¡ered saline
(PBS). Cellular viability was examined by trypan blue dye exclusion
and was always s 95%. The monoclonal B cell line RAJI and the
promyelocytic cell line HL-60 were cultivated in RPMI 1640 medium,
supplemented with 10% fetal bovine serum, 100 Wg/ml streptomycin
and 100 units/ml penicillin and grown in a humidi¢ed atmosphere
with 5% CO2. The source of CD34 positive human blood progenitor
cells (stem cells) was leukapheresis products harvested after treatment
with granulocyte-colony stimulating factor. Cells were puri¢ed with
MiniMACS Magnetic Separation System and MACS CD34 progeni-
tor Cell Isolation Kit (QBEND/10). CD34 positive cells were analyzed
with Coulter for the expression of CD34, CD38, CD33 and HLA-Dr.
The source of human myeloblasts was previously Ficoll-Isopaque sep-
arated and frozen peripheral blood myeloblasts collected at diagnosis
or relapse from adult patients with acute myeloid leukemia (AML),
FAB (French American British) subtypes, M1, M2, M4, M5a and
M5b. The results show that the purity of the progenitor cells or
myeloblasts used in this study was above 98%. All patient samples
were taken after informed consent from the patients. This investiga-
tion has been approved by the Ethics Committee at Karolinska Hos-
pital.
2.3. Isolation of total cellular RNA and RT-PCR
Total cellular RNA was isolated using Trizol Reagent (Life Tech-
nologies) according to the instructions of the manufacturer. Total
RNA (2 Wg) was submitted to reverse transcription reaction using
reverse transcriptase (USB) and oligo-dT primers. PCR was carried
out using 2 Wl of the reverse transcription reaction mixture. The con-
ditions for PCR reactions were 94‡C for 5 min, followed by 40 cycles
of 94‡C for 30 s, 60‡C for 30 s, 72‡C for 30 s and ¢nally extension at
72‡C for 10 min. In order to determine if the isolated cDNA was
intact, PCR ampli¢cation of a L-actin fragment was performed
(data not shown). Primers used for PCR were: iPLA2 primer 33
(sense: 5P-CAGGGCTCTGCAGCGCCACATCAT-3P) ; iPLA2 prim-
er 34 (anti-sense: 5P-GGCCTTCTCGATGGCGATGAGGAG-3P).
2.4. Puri¢cation of cytosolic calcium-independent PLA2 and iPLA2
assay
Human granulocytes were resuspended in bu¡er A (20 mM Tris-
HCl (pH 8.0), 1 mM EDTA, 1 mM EGTA, 0.5 mM dithiotreitol
(DTT)) supplemented with 1 mM phenylmethanesulfonyl £uoride
(PMSF) and homogenized by sonication three times for ¢ve seconds.
Supernatant was obtained after centrifugation at 100 000Ug for 60
min. Liquid chromatography was performed on a Pharmacia FPLC
System. The 100 000Ug supernatant was applied to a 6-ml anion
exchange Resource-Q column, preequilibrated with bu¡er A. After
washing, bound proteins were eluted by a 20-ml linear gradient
from 0 to 1 M NaCl. Fractions of 1 ml were collected and 150-Wl
aliquots of these were assayed for iPLA2 activity. iPLA2 activity was
assayed with 1-palmitoyl 2-[1-14C]palmitoyl phosphatidylcholine (PC)
as substrate. The phospholipids were dried under nitrogen and resus-
pended in 250 Wl of bu¡er A supplemented with 1 mg/ml albumin and
10% glycerol, thus yielding a ¢nal concentration of 2 WM PC. This
preparation was vortexed and sonicated in a water bath for 10 min at
4‡C. The reaction was initiated by adding 150-Wl aliquots of each
fraction and allowed to proceed for 60 min at 37‡C. Subsequently,
the reaction was terminated by the addition of 2 volumes of methanol
containing 0.5% acetic acid and 40 WM stearic acid, as carrier, fol-
lowed by vigorous vortexing.
2.5. Incubation of intact cells and broken cell assay
Human granulocytes (107) were suspended in PBS (1 ml) and pre-
incubated for 10 min at 37‡C with or without BEL as indicated.
Subsequently, calcium ionophore A23187 was added and the samples
were incubated for 10 min at 37‡C and terminated by the addition of
1 ml of methanol. For the broken cell assay, cells (107) were sus-
pended in Ca2-free PBS (1 ml) supplemented with 1 mM EDTA
and sonicated three times for ¢ve seconds on ice. BEL was added
10 min prior to the addition of ATP (1 mM), CaCl2 (2 mM) and
arachidonic acid (20 WM). The samples were thereafter incubated for
10 min at 37‡C and subsequently terminated by the addition of 1 ml
of methanol.
2.6. Measurement of [3H]arachidonic acid release
Human granulocytes were resuspended at 2U106/ml in RPMI 1640
medium containing 0.25 WCi/ml [3H]arachidonic acid and incubated
for 60 min at 37‡C. Thereafter, cells were centrifuged and washed
twice to remove unincorporated arachidonic acid. Labeled cells
(107) were resuspended in 1 ml PBS containing 1 mg/ml of fatty
acid free albumin. The samples were incubated with or without
BEL for 10 min at 37‡C prior to the addition of 0.15 WM A23187
and thereafter incubated for another period of 10 min. The reaction
was terminated with 1 volume of methanol.
2.7. Analysis of leukotrienes and free fatty acids
Methanol precipitated samples were centrifuged and the resulting
supernatants were applied to octadecyl reverse-phase columns (Chro-
mabond, C18, 100 mg, Macherey-Nagel, Duºren, Germany). The ex-
tracted samples were analyzed in a reverse-phase (RP) HPLC system.
The mobile phase was methanol/water/tri£uoroacetic acid 70:30:0.007
(by vol.) for leukotrienes and monohydroxy acids. Elution of arach-
idonic acid was accomplished by using a mobile phase of methanol/
water/tri£uoroacetic acid 85:15:0.007 (by vol.) at a £ow rate of 1.2
ml/min. Analysis was performed by comparing retention times with
authentic standards. Radioactivity was detected with a L-RAM HPLC
£ow-through monitor system (Inus System, USA) using Mono£ow 2
scintillation liquid coupled on-line to UV-spectrophotometers. Quan-
titative determination was performed by peak area integration.
2.8. Other procedures
Subcloning of PCR fragments into pCR2.1 was done using TOPO
TA Cloning kit (Invitrogen) and the cDNA insert was sequenced
using ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction
kit (Perkin Elmer) and an ABI 373A automated DNA sequencer.
Protein content was measured with a kit (Bio-Rad) against bovine
serum albumin as the standard protein. Statistical analysis was per-
formed with Student’s paired t-test.
3. Results and discussion
3.1. Expression of 88-kDa iPLA2 and its splice variants in
immature and mature myeloid cells
The selective expression of calcium-dependent cPLA2
mRNA in lymphopoiesis has previously been described [22].
To determine the expression of the 88-kDa iPLA2 mRNA in
myelopoiesis, RT-PCR analysis was performed on total RNA
isolated from various myeloid cells. In these experiments, im-
mature myeloid cells were isolated from patients with acute
myeloid leukemia (AML). The di¡erentiation of myeloid tu-
mor cells is blocked at an early speci¢c stage in AML.
Although these cells are malignant, they represent cell clones
at various stages of di¡erentiation, and can be used to inves-
tigate the expression of genes early in the di¡erentiation proc-
ess. Cells of di¡erent maturity, from the pluripotent blood
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progenitor cell to the terminal di¡erentiated granulocyte, were
investigated as outlined in Fig. 1. Ampli¢cation of a fragment
with the expected size, 237 bp, was observed in all examined
cDNAs. Interestingly, fragments of the isoforms of this
iPLA2, containing just the ankyrin repeats and not the active
site, were easily ampli¢ed: ankyrin-iPLA2-1 (isoform 1) was
ampli¢ed to various extents in all reactions (289-bp fragment)
whereas ankyrin-iPLA2-2 (isoform 2) was ampli¢ed to a high-
er extent when using cDNA derived from the more immature
cells (341-bp fragment) (Fig. 1). The expression of the ankyrin
forms of iPLA2 in myeloid cells would attenuate the iPLA2
activity in immature cells since these forms may act as in vivo
inhibitors. The identity of the PCR-derived fragments was
veri¢ed by subcloning into pCR2.1 and subsequent sequenc-
ing using m13 forward and reverse primers (data not shown).
Taken together, these results demonstrate that the iPLA2 gene
is constitutively expressed in the examined cells. However, the
expression of alternatively spliced variants di¡ers in the inves-
tigated cells.
3.2. Neutrophil cytosol contains iPLA2 activity
To investigate if granulocytes possess iPLA2 activity, the
cytosol from granulocytes was subjected to anion-exchange
chromatography using a Resource-Q column. The
100 000Ug supernatant was applied to the column and bound
proteins were eluted using a linear gradient from 0 to 1 M
NaCl. Aliquots of each fraction were incubated with or with-
out BEL and incubated for 60 min under calcium-free con-
ditions in the presence of radiolabelled phospholipids. The
results outlined in Fig. 2 indicate that there is one major
chromatographical resolvable iPLA2 activity that is inhibited
by BEL. Furthermore, the observed pro¢le of iPLA2 activity
is in accordance with the elution pattern of the murine 85-kDa
iPLA2 enzyme, eluting with low salt wash, puri¢ed from the
macrophage-like cell line P388D1 [7].
3.3. E¡ects of BEL on leukotriene formation in granulocytes
Calcium ionophore A23187 has been demonstrated to in-
duce the release of arachidonic acid even in the absence of
increased intracellular calcium concentrations [13]. This BEL-
inhibitable calcium-independent release of arachidonic acid is
suggested to be coupled to the depletion of intracellular cal-
cium stores [13]. Ionophore A23187 readily penetrates the
plasma membrane and can thereby mediate the passive trans-
port of calcium ions from intracellular stores and induce cal-
cium depletion from these sites. Since BEL inhibited the ac-
tivity of iPLA2 in the cytosolic fraction from neutrophils (Fig.
2), the role of BEL-sensitive enzymes in leukotriene synthesis
in granulocytes was investigated. Intact granulocytes were
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Fig. 3. Dose-response e¡ects of BEL on ionophore A23187-induced
LTB4 formation in human granulocytes. Human granulocytes (107)
were incubated with indicated concentrations of BEL for 10 min at
37‡C and subsequently stimulated with 0.1 WM A23187 for another
period of 10 min. The results are expressed as formation of LTB4
(pmol/106 cells). Data show the mean þ S.D., n = 5 (***P6 0.001 vs.
control and **P6 0.01 vs. control).
Fig. 2. Elution pro¢le of proteins and iPLA2 activity from an anion
exchange column. Human granulocytes were resuspended in bu¡er
and homogenized by sonication for three times ¢ve seconds. Super-
natant was obtained after centrifugation at 100 000Ug for 60 min.
The 100 000Ug supernatant was applied to a 6-ml anion exchange
Resource-Q column. After washing, bound proteins were eluted by
a 20-ml linear gradient from 0 to 1 M NaCl. Fractions of 1 ml
were collected and 150-Wl aliquots of each fraction were assayed for
iPLA2 by incubation for 60 min with 2 WM 1-palmitoyl
[2-14C]palmitoyl PC as substrate without (^ b ^) or with (^ b ^)
10 WM BEL as described in Section 2. The results are expressed as
the amount of free [14C]palmitic acid (cpm) in each analyzed ali-
quot.
Fig. 1. RT-PCR analysis of iPLA2 and its two splice variants. RT-
PCR analysis of total RNA from di¡erent cells was performed as
described in Section 2. A 10-Wl aliquot of ampli¢ed material was an-
alyzed on a 1.5% agarose gel, containing ethidium bromide. Arrows
on the left indicate the size marker in bp. Arrows on the right indi-
cate the position of the di¡erent splice variants of the iPLA2 tran-
script. The source of CD34 positive human blood progenitor cells
(stem cells) was leukapheresis product. The source of human myelo-
blasts was previously Ficoll-Isopaque separated and frozen periph-
eral blood myeloblasts collected at diagnosis or relapse from adult
patients with acute myeloid leukemia (AML), FAB subtypes, M1,
M2, M4, M5a and M5b. The purity of the blood progenitor cells or
myeloblasts used in this study was more than 98%. HL-60: promye-
locytic cell line; RAJI: monoclonal B cell line.
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stimulated with increasing concentrations of BEL and low-
dose ionophore A23187 (0.10^0.15 WM). At these concentra-
tions of ionophore A23187, minimal amounts of the non-en-
zymatically products of LTA4, i.e. 6-trans-LTB4 and 6-trans-
12-epi-LTB4, were formed (data not shown). As depicted in
Fig. 3, BEL dose-dependently inibited leukotriene synthesis,
induced by 0.10 WM ionophore A23187. In another set of
experiments, using 0.15 WM calcium ionophore A23187, a
69% inhibition of the formation of 5-lipoxygenase products
was observed with 5 WM BEL. The total amounts of 5-lipo-
xygenase products, i.e. LTB4, 6-trans-LTB4, 6-trans-12-epi-
LTB4 and 5-hydroxyeicosatetraenoic acid (5-HETE), were
46.8 þ 6.4 and 15.2 þ 8.3 pmol/106 cells (data is mean þ range
from two experiments performed in duplicate) in control and
BEL treated cells, respectively. The inhibitory e¡ect of BEL
on LTB4 formation at higher concentrations of A23187 (1 WM)
was not as prominent as with low concentrations of
ionophore A23187. The formation of 6-trans-LTB4, 6-trans-
12-epi-LTB4 and 5-HETE was at these higher ionophore con-
centrations the major products and the inhibitory e¡ect of
BEL was mainly observed on the formation of these products
(data not shown). Thus, the formation of 5-lipoxygenase
products after stimulation with high concentrations of iono-
phore A23187 indicates that the cells’ capacity to release
arachidonic acid is not rate-limiting in LTB4 formation but
instead the activity of 5-lipoxygenase and LTA4 hydrolase.
These results indicate that there are BEL-insensitive mecha-
nisms involved in the release of arachidonic acid destined for
leukotriene synthesis. These mechanisms are likely to involve
the calcium-dependent PLA2s. Several lines of evidence sug-
gest that calcium-dependent cPLA2 plays a key role in the
formation of leukotrienes A23187 [17,18]. However, the
main PLA2 activity at low concentrations of ionophore
A23187 is inhibited by BEL and might therefore be ascribed
to iPLA2 enzymes, indicating that iPLA2 is of importance for
leukotriene synthesis under certain conditions.
In order to investigate the role of iPLA2 on leukotriene
synthesis induced by a more physiological stimulus, granulo-
cytes were incubated with opsonized zymosan for 10 min in
the presence or absence of BEL. Cells stimulated with opson-
ized zymosan alone produced 4.3 þ 0.5 pmol LTB4/106 cells.
Incubation of granulocytes with BEL (10 WM) for 10 min
prior to the addition of opsonized zymosan resulted in the
production of 1.7 þ 0.5 pmol LTB4/106 cells (data is mean þ
range from two separate experiments), thus resulting in a 60%
reduction of the amounts of LTB4.
To investigate if BEL possessed any direct inhibitory e¡ects
on 5-lipoxygenase, cellular homogenates of granulocytes were
incubated with BEL. The synthesis of leukotrienes in homo-
genates of granulocytes was initiated by the addition of cal-
cium, ATP and 20 WM exogenous arachidonic acid. In such
experiments, BEL (10 WM) had no e¡ect on 5-lipoxygenase
activity and the levels of 5-lipoxygenase products were
380.8 þ 75.5 and 399.3 þ 77.3 5 pmol/106 cells (data is
mean þ SD from three experiments performed in duplicate)
in the absence or presence of BEL, respectively.
3.4. E¡ects of BEL on arachidonic acid release
BEL is reported to be about 1000-fold more speci¢c for
iPLA2 in comparison to cPLA2. Experiments were employed
to investigate the e¡ects of BEL on ionophore A23187-in-
duced arachidonic acid release in human granulocytes. Cells
were labelled with [3H]arachidonic acid for 60 min prior to the
addition of BEL or ethanol (control). Cells stimulated with
0.15 WM ionophore A23187 alone released 4230 þ 40 cpm of
[3H]arachidonic acid. However, preincubation of the cells with
10 WM BEL for 10 min prior to stimulation with ionophore
A23187 led to decreased amounts of free [3H]arachidonic acid
(2370 þ 20 cpm cells) (mean þ range from one representative
experiment, out of two, performed in duplicate). These results
demonstrate that BEL inhibited the release of arachidonic
acid in granulocytes, activated with low concentration of cal-
cium ionophore. BEL was not cytotoxic to granulocytes since
cells exposed to 10 WM BEL for 20 min at 37‡C demonstrated
similar viability as the control (data not shown).
3.5. Phosphatidic acid phosphohydrolase and leukotriene
formation
Although BEL displays selectivity between di¡erent PLA2
enzymes it does, however, inhibit cytosolic magnesium-de-
pendent phosphatidic acid phosphohydrolase (PAP-1) at sim-
ilar concentrations as for iPLA2 [23]. Therefore, when em-
ploying BEL, caution should be taken when interpreting
results. Since granulocytes contain PAP activity, and in fact
20% of the total PAP activity is cytosolic (PAP-1) [24], the
potential involvement of PAP-1 in ionophore A23187-induced
leukotriene synthesis in granulocytes was investigated. Propra-
nolol, a PAP inhibitor, dose-dependently inhibits degranula-
tion and activation of NADPH-oxidase in granulocytes at a
concentration of 50^100 WM [25]. Furthermore, propranolol
inhibits fMLP-induced formation of diacylglycerol (DAG),
which is a possible source of arachidonic acid [26]. In order
to determine whether the e¡ect of BEL on leukotriene syn-
thesis was mediated through inhibition of PAP, cells were
preincubated with propranolol (250 WM solved in dimethyl-
sulfoxide (DMSO)) or DMSO for 10 min and subsequently
stimulated with 0.15 WM ionophore A23187 for another peri-
od of 10 min. The formation of 5-lipoxygenase products was
31.4 þ 11.0 and 31.0 þ 10.5 pmol/106 cells (data is mean þ
range from two experiments performed in duplicate), in the
absence or presence of propranolol, respectively. These results
indicate that the inhibitory action of BEL on leukotriene syn-
thesis was not due to inhibition of PAP-1. On the contrary,
when using 50^100 WM propranolol, a slight increase in the
formation of 5-lipoxygenase metabolites was observed (data
not shown).
In a recent report it was demonstrated that di¡erent PLA2
enzymes are involved in the release of arachidonic acid des-
tined for eicosanoid synthesis or activation of NADPH oxi-
dase [15]. Interestingly, the production of superoxide anions
and eicosanoid synthesis was stimulus speci¢c. Calcium ion-
ophore A23187 induced arachidonic acid release and eicosa-
noid synthesis but was unable to promote superoxide produc-
tion. On the other hand, polychlorinated biphenyls induced
both arachidonic acid release, eicosanoid synthesis and super-
oxide production. The eicosanoids accounted for 6 20% of
the radioactive metabolites recovered from the neutrophils
when stimulated with polychlorinated biphenyls. The release
of arachidonic acid induced by polychlorinated biphenyls was
blocked by BEL [15].
A general consensus has been that an increase of intracel-
lular calcium is the primary event for activation of cellular
calcium-dependent PLA2s and hence the release of arachi-
donic acid utilized for eicosanoid synthesis. However, the
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¢ndings of this and of other recently published studies suggest
that there are alternative calcium-independent mechanisms for
release of arachidonic acid [13,15,27]. In conclusion, this study
demonstrates the expression of the 88-kDa iPLA2 mRNA and
its two splice variants, ankyrin-iPLA2-1 and ankyrin-iPLA2-2,
in immature and mature myeloid cells. Studies with BEL sug-
gest that iPLA2 is involved in leukotriene synthesis in gran-
ulocytes, upon activation with low concentration of ionophore
A23187 or opsonized zymosan. Although calcium-dependent
cPLA2 apparently has an essential role in the release of arach-
idonic acid destined for leukotriene synthesis, it is likely that
iPLA2 is also involved in leukotriene synthesis under certain
physiological conditions.
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